Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Sigrid Therapeuctis AB on share issues
Mandate

Vinge advises Sigrid Therapeuctis AB on share issues

November 27, 2017

Vinge has advised Sigrid Therapeuctis AB in connection with a combined directed issue and rights offering.

Sigrid Therapeutics is pioneering a user-friendly product made of precisely engineered particles with extraordinary absorptive capacity. The product works mechanically in the gut to improve glycemic control in a safe and effective way.

Vinge’s team primarily consisted of Kristoffer Franzkeit and Astrid Karlsson.

Related

Vinge advises Wihlborgs Fastigheter in connection with the financing of property acquisition valued at SEK 13.3 billion

 Vinge advises Wihlborgs Fastigheter AB (publ) in connection with the financing of the acquisition of all of Castellum’s property holdings in Malmö, Lund and Helsingborg. The financing has been secured through Danske Bank, SEB and Swedbank.
June 29, 2026

Vinge advises Ambea on the public offer for Humana

 Ambea AB (publ) has made a public offer for all shares in Humana AB. The offer values all shares in Humana at approximately SEK 2,96 billion. The consideration consists of a mix of shares, cash and a CVR (contingent value right).
June 29, 2026

Vinge has advised Gamma Waves on Sportway’s EUR 20 million financing round

 Vinge has acted as legal adviser to Gamma Waves in connection with Sportway’s EUR 20 million financing round. The round was led by Gamma Waves, together with continued participation from existing shareholders, and values Sportway at approximately EUR 92 million (around SEK 1 billion) post-money.
June 24, 2026